Home
overview

The global diabetes market is projected to double from $32bn to $64bn over the next 15 years as a result of changing demographics and new therapies entering the clinic.


Now at epidemic levels, diabetes will affect eight percent of the world’s adult population by 2030. As the number of diabetics grows, so too will the need for new treatments to mitigate the effects of diabetes-related disorders and diseases. With this in mind, SMi is very proud to present our 11th conference focusing on Diabetes, Secondary Complications, Regulation and  Innovation. The conference will take place on the 1st and 2nd October 2013 and will provide a unique platform to engage with industry professionals, KOLs and esteemed academia in the field of diabetic and metabolic disease. With a spotlight on areas such as: combination therapy, diabetic retinopathy, stem cell and islet technology and EU and FDA guidelines, Diabetes 2013 promises to be a truly unmissable event!

  • From concept to clinical practice: identify novel therapeutic targets
  • Keep well informed with new EU and FDA guidelines on clinical trials and risk-benefit assessment
  • Identify successes in clinical development and efficacy studies
  • Receive clinical updates on novel receptor agonists e.g. SLGT2 and DPP-4 inhibitors
  • Discuss future medicine and the role of synthetic biology
  • Discover methods to reduce costs in large scale outcome trials
  • Validate target engagement biomarkers
  • Build relationships with key industry and academic professionals
Chief Executives, Chief Scientific Officers, Presidents, Senior Vice Presidents, Vice Presidents, Heads, Senior Directors, Directors, Clinicians, Principal Scientists, Principal Investigators, Managers, Project/Team Leaders in:
  • Diabetes & Obesity, Clinical R&D
  • Renal and Kidney Diseases
  • Endocrinology and Metabolic Diseases
  • Cardiovascular and Gastrointestinal Diseases
  • Anti-Diabetic Agents & Advanced Diabetes Systems
  • Biomarkers
  • Imaging and Translational Medicine
  • Drug Development
  • Monoclonal Antibodies
  • Molecular Neuroscience
  • New Products Global Marketing
  • Business Development, Licensing & Partnership
  • Venture Capital
 

Afea S.A.; Astra Zeneca; AstraZeneca; Boehringer Ingelheim; Boehringer Ingelheim Pharma AG; Bristol-Myers Squibb; Bristol-Myers Squibb Pharmaceuticals Ltd; Coventry university; EDO STATE HOSPITAL MANAGEMENT BOARD; Four New Square; Fresenius Medical Care Deutschland; Glaxo SmithKline Ltd ; Imperial College Of Science Technology & Medicine; Institute of Ophthalmology, University College London; Kings College London; Loughborough University; Madrigal Pharmaceuticals; Medicines Assessment Ltd ; Merck Sharp & Dohme ; Merck Sharp & Dohme Ltd; MHRA; Nottingham University; Novo Nordisk A / S; Quintiles; Relypsa; UCL; University College London; University Hospital Aintree; University of London; University of Maastricht; University Of Oxford.
 

Conference programme

8:30 Registration & Coffee

9:00 Chairman's Opening Remarks

Philip Ambery

Philip Ambery, Director, Clinical development, Glaxo SmithKline Ltd

John Warren

John Warren, Director, Medicines Assessment Ltd

9:10 From concept to clinical practice: therapeutic targets to reduce disease in type 2 diabetes

Philip Ambery

Philip Ambery, Director, Clinical development, Glaxo SmithKline Ltd

  • Learnings about the pathophysiology of diabetic complications
  • Can these learnings deliver potential new drug targets? (data from early / mechanistic studies)
  • Are there common targets between Type 1 and 2 diabetes?
  • 9:50 Thinking outside the box: For the identification of novel targets for diabetes treatment

    Itzik Harosh

    Itzik Harosh, President & Chief Executive Officer, Obe Therapy Biotechnology

  • Past and present gene targets in obesity and diabetes
  • Starvation phenotype as source for new gene targets for diabetes treatment
  • Rare genetic diseases as a clue for identification of new targets for common metabolic syndrome
  • Knock-out of the enteropeptidase gene in mice
  • 10:30 Morning Coffee

    11:00 Innovation in Diabetes: needs, trends and outcome

    Tomas Landh

    Tomas Landh, Director, Strategy and Sourcing Diabetes Research Unit, Novo Nordisk A/S

  • Current challenges associated with drug development
  • New strategic modes of accessing innovation
  • Trends and outcome measures
  • Future of innovation
  • 11:40 Diabetes: future medicine and the role of synthetic biology

    Nigel Sansom

    Nigel Sansom, Managing Director, Celaris Biosystems

  • State of the Art and the story so far
  • Prospects for synthetic biology as a viable treatment
  • Possible future therapeutics
  • 12:20 Networking Lunch

    13:40 Diabetology: oral delivery of insulin and other diabetes therapies

    Timothy Broke-Smith

    Timothy Broke-Smith, Chief Operating Officer, Diabetology

  • Axcess™ convenient oral delivery of peptides that would otherwise require injection: how it works and the benefits it can provide
  • Capsulin™ oral insulin: clinical progress and strengths for treating diabetes
  • Oral GLP-1 and other oral antidiabetic therapies in development
  • 14:20 Diabetes...So What? Serious and up-to-date answers to this question

    Wim  Wientjens

    Wim Wientjens, Ambassador, International Diabetes Federation

  • Three processes, three roles
  • Being a normal member of society
  • Insulin and injection systems
  • The Health Care Inspectorate
  • The false hope of an international care standard
  • 15:00 Afternoon Tea

    15:30 A toolkit for CCGs to put their diabetes pathways under patient control

    Mohammad Al-Ubaydli

    Mohammad Al-Ubaydli, CEO, Patients Know Best

  • The patient is the one with the data and the one making the decisions day-to-day
  • Diabetes clinicians should be at the forefront of putting the patient in control of data and decisions
  • Patient control brings consumer-level prices and usability into health care
  • 16:10 Vitamin D and diabetic nephropathy

    Frederick W K Tam

    Frederick W K Tam, Reader in Renal Medicine, Imperial College London West London Renal and Transplant Centre Hammersmith Hospital

  • Vitamin D and the immune system
  • Vitamin D – effect on progression of diabetic nephropathy
  • Variation in vitamin D – a potential confounding factor in clinical trials
  • 16:50 Chairman's closing remarks and end of Day One

    8:30 Registration & Coffee

    9:00 Chairman's Opening Remarks

    Peter Feldschreiber

    Peter Feldschreiber, Senior Medical Assessor, Four New Square

    John Warren

    John Warren, Director, Medicines Assessment Ltd

    9:10 Benefit: risk as seen by the regulator and the court

    Peter Feldschreiber

    Peter Feldschreiber, Senior Medical Assessor, Four New Square

  • Risk/benefit assessments: clinical prognostic risk, socio-economic and environmental risks, consumer protection, intellectual property, commercial risks and risk of criminal sanctions
  • Risk/benefit profile: current international legislation and regulatory objectives for medicinal products
  • Examples of regulatory failure: Vioxx, Seroxat, the glitazones and TGN1412
  • 9:50 Cardiovascular risk in diabetes: shifting regulatory perspective

    John Warren

    John Warren, Director, Medicines Assessment Ltd

  • FDA's response to Glitazones
  • FDA's response to obesity drugs
  • Litigation and risk >2
  • EU regulatory position
  • Implications of cardiovascular safety threshold for efficacy assessment
  • 10:30 Morning Coffee

    11:00 MGL-3196 liver-directed thyroid hormone beta agonist, a novel treatment for diabetic dyslipdemia

    Rebecca Taub

    Rebecca Taub, CEO, Madrigal Pharmaceuticals

  • Diabetes is associated with a dyslipidemia characterized by fatty liver, elevated triglycerides (TGs), atherogenic LDL particles and low HDL cholesterol.
  • Fatty liver is a cause of liver insulin resistance and non-alcoholic steatohepatitis (NASH) and is associated with increased CV disease. 
  • MGL-3196 reduces LDL cholesterol and triglycerides in Phase 1 studies in humans, and also reduced fatty liver in preclinical models of fatty liver disease

  •  

    11:40 Manipulation of a short-activating RNA oligonucleotide targeting the islet ß-cell transcriptional factor MafA in CD34+ cells

    Nagy Habib

    Nagy Habib, Professor Department of Surgery & Cancer, Imperial College London

  • Bioengineering surrogate insulin producing cells, an alternative replacement strategy
  • A novel approach using short-activating RNA oligonucleotides
  • Transfecting RNA to increase transcript levels of the master regulator of insulin biosynthesis
  • Developing insulin producing surrogate cells for treating diabetes
  • 12:20 Networking Lunch

    13:50 Diabetes secondary complication: hypoglycaemia

    Haya Langerman

    Haya Langerman, Medical Advisor, Merck Sharp & Dohme Ltd

  • What is it?
  • What are the consequences?
  • Improving the management of hypoglycaemia in type 2 diabetes
  • Insight into the SU pharmacy survey
  • 14:30 Dapagliflozin vs Glipizide as add-on therapy in patients with Type 2 diabetes

    Katja Rohwedder

    Katja Rohwedder, Medical Director, AstraZeneca GmbH

    15:10 Afternoon Tea

    15:40 Epigenetic mechanisms linking diabetes and synaptic impairment in Alzheimer’s disease and other forms of dementia

  • Differential regulation of epigenetic modifier histone deacetylase (HDAC) IIa is associated with impaired synaptic integrity in the brains of diabetic Alzheimer’s disease subjects
  • In experimental model of diabetes, diabetic condition promotes HDAC IIa in the brain; prolonged diabetic condition is associated with increased susceptibility to neurodegeneration
  • Pharmacological Inhibition of HDAC IIa in diabetes restores synaptic function, promotes synaptic plasticity, and enhances learning and memory functions
     
  • Giulio Pasinetti

    Giulio Pasinetti, The Saunders Family Chair and Professor in Neurology, Icahn School of Medicine at Mount Sinai

    16:20 PANEL DISCUSSION: Microvascular Complications of diabetes: major burden & unmet need

  • Current considerations and major challenges of early diagnosis and management of Diabetic nephropathy, Neuropathy, Foot Ulcer & Retinopathy
  • Disease modifying therapy:
  • Is it possible to halt or reverse complications?
  • How can that be accomplished?
  • How Academia, Industry and Advocacy groups can work together to address this unmet medical need?
  • What lies ahead for the future?
     
  • Haya Langerman

    Haya Langerman, Medical Advisor, Merck Sharp & Dohme Ltd

    Peter Feldschreiber

    Peter Feldschreiber, Senior Medical Assessor, Four New Square

    John Warren

    John Warren, Director, Medicines Assessment Ltd

    17:00 Chairman’s Closing Remarks and Close of Day Two

    +

    FEATURED SPEAKERS

    Haya Langerman

    Haya Langerman

    Medical Advisor, Merck Sharp & Dohme Ltd
    Katja Rohwedder

    Katja Rohwedder

    Medical Director, AstraZeneca GmbH
    Natalia Borinshteyn

    Natalia Borinshteyn

    Head of Diabetes Prevention and Complications, Sanofi-Aventis SA
    Peter Feldschreiber

    Peter Feldschreiber

    Senior Medical Assessor, Four New Square
    Philip Ambery

    Philip Ambery

    Director, Clinical development, Glaxo SmithKline Ltd
    Tomas Landh

    Tomas Landh

    Director, Strategy and Sourcing Diabetes Research Unit, Novo Nordisk A/S

    Frederick W K Tam

    Reader in Renal Medicine, Imperial College London West London Renal and Transplant Centre Hammersmith Hospital
    Frederick W K Tam

    Giulio Pasinetti

    The Saunders Family Chair and Professor in Neurology, Icahn School of Medicine at Mount Sinai
    Giulio Pasinetti

    Haya Langerman

    Medical Advisor, Merck Sharp & Dohme Ltd
    Haya Langerman

    Itzik Harosh

    President & Chief Executive Officer, Obe Therapy Biotechnology
    Itzik Harosh

    Dr Itzik Harosh is the founder & CEO of ObeTherapy a biotech dedicated to the discovery of new genes for obesity and diabetes treatment based on the lean phenotype and the development of molecules for the treatment of metabolic syndrome. Establish the concept to look for genes associated to starvation phenotye for the treatment of obesity and type II diabetes.
    Priore to the creation of ObeTherapy he was a Group leader in GSK in France where he learned the art of drug discovery, targets identification and validation.
    Dr. Harosh did his PhD at The Weizmann Institute of Science in Israel, working on DNA repair enzymes which was followed by four years of post doctoral experience at Stanford and at Davis University, California, US. From there he moved to France where he worked in the CNRS at the laboratory of Miro Radman. Dr. Harosh is the author and co-author of 15 articles and 8 patents all dealing with obesity, diabetes and HTS.
    Dr. Harosh is on the editorial board of; Journal of US-China Medical Science and is regularly invited to international Obesity, Diabetes and metabolic syndrome conferences.
    Before the creation of ObeTherapy, Itzik was a Group leader in GSK where he learned the art of drug discovery, targets identification and validation. Itzik also has four years of post doctoral experience at Stanford and the University of California at Davis working on DNA repair.

    John Warren

    Director, Medicines Assessment Ltd
    John Warren

    Katja Rohwedder

    Medical Director, AstraZeneca GmbH
    Katja Rohwedder

    Mohammad Al-Ubaydli

    CEO, Patients Know Best
    Mohammad Al-Ubaydli

    Nagy Habib

    Professor Department of Surgery & Cancer, Imperial College London
    Nagy Habib

    Natalia Borinshteyn

    Head of Diabetes Prevention and Complications, Sanofi-Aventis SA
    Natalia Borinshteyn

    Nigel Sansom

    Managing Director, Celaris Biosystems
    Nigel Sansom

    Peter Feldschreiber

    Senior Medical Assessor, Four New Square
    Peter Feldschreiber

    Philip Ambery

    Director, Clinical development, Glaxo SmithKline Ltd
    Philip Ambery

    Rebecca Taub

    CEO, Madrigal Pharmaceuticals
    Rebecca Taub

    Timothy Broke-Smith

    Chief Operating Officer, Diabetology
    Timothy Broke-Smith

    Tomas Landh

    Director, Strategy and Sourcing Diabetes Research Unit, Novo Nordisk A/S
    Tomas Landh

    Wim Wientjens

    Ambassador, International Diabetes Federation
    Wim  Wientjens

    VENUE

    Marriott Regents Park

    128 King Henry's Road, London, United Kingdom

    This 4 star north London hotel in zone 2 is the perfect destination for the astute business traveler as well as the leisure guest that knows how convenient north London hotels are, as a base from which to explore the city .Bond Street is just 3 stops from Swiss Cottage underground station on the Jubilee Line, so you can be shopping, exploring the sights and taking in one of London’s world-renowned West End shows in less than 15 minutes when you stay at this hotel near central London. At the same time, the hive of activity that is Camden Town, the chic shops, cafes and restaurants of Primrose Hill and ZSL’s London Zoo in Regents Park are all just a short walk from this hotel in north London.

    HOTEL BOOKING FORM

    SAVE TO


    Outlook Calendar  OUTLOOK CALENDAR
    Google Calendar  GOOGLE CALENDAR
    ICal Calendar  ICAL CALENDAR
    Yahoo! Calendar  YAHOO! CALENDAR

    Marriott Regents Park

    128 King Henry's Road
    London NW3 3ST
    United Kingdom

    Marriott Regents Park

    This 4 star north London hotel in zone 2 is the perfect destination for the astute business traveler as well as the leisure guest that knows how convenient north London hotels are, as a base from which to explore the city .Bond Street is just 3 stops from Swiss Cottage underground station on the Jubilee Line, so you can be shopping, exploring the sights and taking in one of London’s world-renowned West End shows in less than 15 minutes when you stay at this hotel near central London. At the same time, the hive of activity that is Camden Town, the chic shops, cafes and restaurants of Primrose Hill and ZSL’s London Zoo in Regents Park are all just a short walk from this hotel in north London.

    HOTEL BOOKING FORM

    Title

    SubTitle
    speaker image

    Content


    Title


    Description

    Download


    WHAT IS CPD?

    CPD stands for Continuing Professional Development’. It is essentially a philosophy, which maintains that in order to be effective, learning should be organised and structured. The most common definition is:

    ‘A commitment to structured skills and knowledge enhancement for Personal or Professional competence’

    CPD is a common requirement of individual membership with professional bodies and Institutes. Increasingly, employers also expect their staff to undertake regular CPD activities.

    Undertaken over a period of time, CPD ensures that educational qualifications do not become obsolete, and allows for best practice and professional standards to be upheld.

    CPD can be undertaken through a variety of learning activities including instructor led training courses, seminars and conferences, e:learning modules or structured reading.

    CPD AND PROFESSIONAL INSTITUTES

    There are approximately 470 institutes in the UK across all industry sectors, with a collective membership of circa 4 million professionals, and they all expect their members to undertake CPD.

    For some institutes undertaking CPD is mandatory e.g. accountancy and law, and linked to a licence to practice, for others it’s obligatory. By ensuring that their members undertake CPD, the professional bodies seek to ensure that professional standards, legislative awareness and ethical practices are maintained.

    CPD Schemes often run over the period of a year and the institutes generally provide online tools for their members to record and reflect on their CPD activities.

    TYPICAL CPD SCHEMES AND RECORDING OF CPD (CPD points and hours)

    Professional bodies and Institutes CPD schemes are either structured as ‘Input’ or ‘Output’ based.

    ‘Input’ based schemes list a precise number of CPD hours that individuals must achieve within a given time period. These schemes can also use different ‘currencies’ such as points, merits, units or credits, where an individual must accumulate the number required. These currencies are usually based on time i.e. 1 CPD point = 1 hour of learning.

    ‘Output’ based schemes are learner centred. They require individuals to set learning goals that align to professional competencies, or personal development objectives. These schemes also list different ways to achieve the learning goals e.g. training courses, seminars or e:learning, which enables an individual to complete their CPD through their preferred mode of learning.

    The majority of Input and Output based schemes actively encourage individuals to seek appropriate CPD activities independently.

    As a formal provider of CPD certified activities, SMI Group can provide an indication of the learning benefit gained and the typical completion. However, it is ultimately the responsibility of the delegate to evaluate their learning, and record it correctly in line with their professional body’s or employers requirements.

    GLOBAL CPD

    Increasingly, international and emerging markets are ‘professionalising’ their workforces and looking to the UK to benchmark educational standards. The undertaking of CPD is now increasingly expected of any individual employed within today’s global marketplace.

    CPD Certificates

    We can provide a certificate for all our accredited events. To request a CPD certificate for a conference , workshop, master classes you have attended please email events@smi-online.co.uk

    Event Title

    Headline

    Text
    Read More

    I would like to speak at an event

    I would like to attend an event

    I would like to sponsor/exhibit at an event

    SIGN UP OR LOGIN

    Sign up
    Forgotten Password?

    Contact SMi GROUP LTD

    UK Office
    Opening Hours: 9.00 - 17.30 (local time)
    SMi Group Ltd, 1 Westminster Bridge Road, London, SE1 7XW, United Kingdom
    Tel: +44 (0) 20 7827 6000 Fax: +44 (0) 20 7827 6001
    Website: http://www.smi-online.co.uk Email: events@smi-online.co.uk
    Registered in England No: 3779287 VAT No: GB 976 2951 71




    Forgotten Password

    Please enter the email address you registered with. We will email you a new password.